Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 3Phase 2 3Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 6Breast Neoplasms 4Neoplasm Metastasis 3Glioma 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Astrocytoma 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neoplasms 2Gliosarcoma 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Brain Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Rectal Neoplasms 1Pinealoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroblastoma 1Meningioma 1Medulloblastoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1

Interventions

Gemcitabine 17pembrolizumab 16Cisplatin 14enfortumab vedotin 7avelumab 7Nivolumab 6Docetaxel 6atezolizumab 5Paclitaxel 5Cystectomy 5sacituzumab govitecan 4durvalumab 4Mitomycin 4Cystoscopy 4Carboplatin 4vofatamab 3tremelimumab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3vinflunine 2tisotumab vedotin 2poly ICLC 2cemiplimab 2aldesleukin 2Transurethral Resection of Bladder 2Radiotherapy, Intensity-Modulated 2Ipilimumab 2Interleukin-2 2Immunoglobulin G 2Clinical Trials, Phase II as Topic 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Urinary Bladder Neoplasms × Surgical Procedures, Operative × Clear all
NCT06305767 2026-01-13

INTerpath-005

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
230 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡